Esperion
Cardiometabolic Therapeutics · Prescription Drugs

Esperion: Risk & public record

Esperion: 77 research papers in five years.

Data updated Nov 22, 2026 · Back to the company report

What the registers and the postings say about this employer.

Legal entity active
Esperion Therapeutics, Inc.
Not checked
Sanctions lists
OFAC SDN, EU consolidated · sanctionssearch.ofac.treas.gov ↗
No match
Phishing reports
OpenPhish, Phishing.Database · openphish.com ↗
None
Layoff notices
US WARN notices on file · dol.gov ↗
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Public record

Esperion: 77 research papers in five years.

Research outputpapers its people wrote, per OpenAlex
77papers in five years
15kcitations
Lipoproteins and Cardiovascular Health
Medicine
145 papers
Cholesterol and Lipid Metabolism
Biochemistry, Genetics and Molecular Biology
106 papers
Lipid metabolism and disorders
Medicine
48 papers
Cancer, Lipids, and Metabolism
Biochemistry, Genetics and Molecular Biology
45 papers
Atherosclerosis and Cardiovascular Diseases
Immunology and Microbiology
20 papers

Works most with: Cleveland Clinic, Monash University, Tufts University, Brigham and Women's Hospital, Mass General Brigham, Imperial College London

Regulators
Product recalls (FDA, NHTSA, CPSC)
Recall events
2 products since 2023 · 0 of class I
2
Each line links its register: the agency's page, the EU Transparency Register, the FEC, the USPTO, CourtListener. The fines as the CMS GDPR Enforcement Tracker lists them, each linking the authority’s decision; recalls from the FDA’s enforcement reports.